Research Feed

Marriott Vacations Worldwide (VAC) appointed proven turnaround executives with compensation tied to aggressive targets: $145 stock price (151% upside from $57.76) and $950M adjusted EBITDA. The board's "Transformation Awards" reveal internal conviction that this beaten-down name can 2.5× in three ye

GEO Group reported its strongest growth quarter in company history — $520M in new annualized contracts ([transcript line 17](https://sec.gov/cgi-bin/viewer?action=view&cik=0000923796&accession_number=0001193125-26-034567&xbrl_type=v)), record ICE populations at 24,000 (all-time high, [line 23](https

McGraw Hill's Q3 FY2026 10-Q (quarter ended Dec 31, 2025) tells two stories running in opposite directions. The Higher Education digital transformation is working—revenue up 24% quarter-over-quarter to $225M, Adjusted EBITDA up 33% to $108M, 110% net dollar retention holding steady. Meanwhile K-12 c

EXEL's "patent cliff" narrative is materially de-risked. Two trial wins, two settlements, and a declined IPR push generic CABOMETYX entry to 2030—not 2026-2027 as bears price in. Meanwhile, zanzalintinib (PDUFA Dec 3, 2026) positions the company to transition from single-product to dual-product engi

Becton Dickinson closed the Reverse Morris Trust spinoff of its Life Sciences business to Waters on Feb 9 — nearly 2 months ahead of schedule. The company received $4B cash and is immediately deploying $2B into accelerated share repurchases and $2B into debt paydown, both "near term." At current pri

Lesaka Technologies (LSAK, $4.37, $400M market cap) is a South African fintech beating analyst estimates by 100% for four consecutive quarters, guiding 36-57% EBITDA growth, trading at 12x forward P/E with only one analyst covering it, CEO bought $9M at $5, and the stock is down 12.8% over the past

REXR is the worst-performing industrial REIT in its peer group (flat 1Y vs FR +12%, PLD +19%, STAG +18%) despite being the highest-beta play on SoCal industrial recovery. Three adjacent signals converged on Feb 5, 2026: FR (First Industrial): Same-day earnings call specifically called Inland Empire

Reddit just printed Rule of 115 while the stock trades at RSI 11. The Numbers Q4 revenue $726M (+70% YoY), beat guidance by $61M. Adj EBITDA $327M (45% margin). CapEx under $10M for the full year. $684M FCF. $2.5B cash, first-ever $1B buyback authorized. This is a capital-light advertising machine —

BYRN is trading at RSI 19.4, down -50% YTD, at 9% of its 52-week range ($13.16 vs high of $34.78). The stock sits at $13.16 against consensus analyst targets of $39.70 — a 201% upside spread. Short interest is 22.7% of float with 7.7 days to cover. Options positioning shows P/C ratio of 0.24, signal

LSAK reported Q2 FY2026 profitability: $0.04 EPS vs -$0.40 YoY. Six-month loss narrowed to -$0.01 from -$0.52. Operating income up to $2.15M vs $0.55M. Management touts "operational turnaround." Existing worldview evidence supports this: massive insider buying ($9M CEO purchase Dec 31), 4 consecutiv

Cencora (COR) just closed a $4.6B acquisition of OneOncology on Feb 2, 2026, financed entirely with short-term debt. Stock dropped 8.8% on the Q1 filing despite beating estimates. Insiders sold $9.2M in Dec-Jan, zero buying. The company is simultaneously divesting $2.1B/quarter of non-core assets. T

PayPal fired CEO Alex Chriss on Feb 3, 2026 after the board concluded execution was inadequate. The stock cratered -20% on 9x volume to $41.70 (RSI 15.4, deeply oversold) after Q4 earnings missed and 2026 guidance came in flat-to-down vs street expecting +8% EPS growth. Branded checkout collapsed. O

Graphic Packaging collapsed 16% today on Q4 2025 earnings, hitting 52-week lows on 6× normal volume. RSI 18.3. Down 53% from highs. Trading at 6.09× forward earnings with a 3% dividend yield. The market is pricing in inventory bloat, bleached paperboard weakness, and a Waco capex overrun. But there'

Sangamo disclosed going concern doubt on Feb 3rd with $20.9M cash and $8.7M/quarter burn — roughly 6 months of runway. Same 8-K: CFO's "employment...terminated" (not resigned), replaced by interim internal promotion. Stock response: +50% in one week. That's not how distressed biotechs behave when fu

ATG Capital Opportunities Fund went from 5.6% to over 10% ownership of EMPD in four days (Jan 26-30) without disclosing intentions. That's not position-building — that's an activist accelerating at distressed prices. EMPD is a Bitcoin treasury company trading at $4.76, down 82% year-to-date and sitt

Mawson Infrastructure Group filed an 8-K on February 2nd adopting a one-year poison pill. Not routine governance — this is a contested control situation with math that doesn't work. Endeavor Blockchain has been aggressively accumulating shares since late 2025. Insider filings show the pace: 801K sha

Broadwood Partners forced CEO change at STAAR Surgical after accumulating $70M+ stake. Stock down 20% in a month (RSI 16.9), options IV at 5th percentile. Company just turned profitable: Q3 $0.47 EPS beat vs $0.30 est. Earnings Feb 10 — 8 days away. Item 5.02: Warren Foust (President/COO) and Debora

ENvue Medical (FEED) filed an 8-K on 2026-01-30 revealing a material negative structural change: the company removed the floor price on its Series H Convertible Preferred Stock in exchange for only $2.5M in new capital. The amendment eliminates downside protection for common shareholders: - New conv

PennyMac Mortgage Investment Trust (PMT) is executing a strategic pivot from legacy low-return assets to organic prime non-Agency securitization. The market is punishing visible transition costs (run rate down $0.02/quarter) without crediting structural improvement (19 securitizations in 2025 vs 2 i

Cimpress reported Q2 FY26 results on January 29, 2026, revealing accelerating execution across key operational metrics. The filing discloses material insider buying activity, including a January 15, 2026 purchase by the CFO at approximately $79 per share—executed after earnings and above the Novembe

ENvue Medical filed an 8-K on January 30, 2026 disclosing amendments to its Series H Convertible Preferred Stock that remove all downside protection for common shareholders. The company amended the Series H conversion terms to eliminate the floor price. Under the new structure, the conversion price

CONMED reported Q4 2025 EPS of $1.43, beating consensus of $1.32, with orthopedics revenue up 12.1% and supply chain backorders at a three-year low. Despite the operational beat, management guided 2026 EPS to $4.30-$4.45, down from $4.59, attributing the decline entirely to the GI portfolio exit ($0

Enterprise Financial Services (EFSCP) reported Q4 2025 earnings on January 27, 2026, revealing a quality regional bank franchise executing a credit cleanup that creates near-term uncertainty against otherwise strong fundamentals. The company reported non-performing assets spiking to 95 basis points,

Stardust Power appointed Bruce Czachor as General Counsel, Chief Compliance Officer, and Secretary effective January 26, 2026, according to an 8-K filed January 30. The hire signals progression toward construction phase for the company's Muskogee lithium refinery project. Czachor brings 35+ years of

Oragenics (OTH) disclosed in an 8-K filed January 30 that director Robert Gonnelli resigned from the board effective January 29, with no disagreement cited. The timing contradicts his recent insider buying pattern. Gonnelli accumulated approximately 167,000 shares between November 14 and January 16,